medigraphic.com

2019, Number 3

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2019; 20 (3)

Minimum lipid profile for the diagnostic of the peripheral vascular disease's risk

Álvarez PM, Triana MME, Rodríguez VLE, Torres RX

Language: Spanish
References: 26
Page: 1-14
PDF size: 559.45 Kb.


ABSTRACT

Introduction: The minimum lipid profile is related to atherosclerotic vascular disease, but it is not known what is the most common type in adults and the kind of risk it represent for peripheral vascular disease of the lower limbs.
Objective: To determine if the minimum lipid profile is used to diagnose the risk of peripheral vascular disease of the lower limbs.
Methods: It was carried out a study with 533 blood sample of adults from different municipalities in Havana province. Concentrations of total cholesterol and triglycerides were quantified. Average and standard deviation were calculated. Hyperlipidemia was diagnosed and classified, the risk of peripheral vascular disease of the lower limbs and the association of the latter with hyperlipidemia were identified. The level of reliability used was of 95% (α = 0.05).
Results: The most common minimum lipid profiles were: mild hypercholesterolemia (46%) and hypertriglyceridemia (22.6%). 53.8% presented a risk of peripheral vascular disease of the lower limbs between potential (24.8%) and high (29%). There was a relation between the hyperlipidemia and the presence of peripheral vascular diseases of the lower limbs (Chi square= 120.4; p = 0.00000). It was detected that 50% of the people required a hypolipidemic treatment.
Conclusion: The minimum lipid profile is used to diagnose the risk's type of peripheral vascular disease of the lower limbs, observing a strong relation of the latter with the presence of hyperlipidemia.


REFERENCES

  1. Aronow HD, Beckman JA. Parsing Atherosclerosis. Circulation. 2016;134(6):438-40.

  2. Libby P, Karin E. Bornfeldt KE, Tall AR. Atherosclerosis successes, surprises, and future challenges. Circ Res. 2016;118:531-4. doi: 10.1161/CIRCRESAHA.116.308334.

  3. Nakano M, Stephen J, Kramer MCA, Ladich ER, Kolodgie FD, Virmani R. Insights into the natural history of atherosclerosis progression. In: Taylor AJ, Villines TC, editors. Atherosclerosis: Clinical perspectives through imaging. London: Springer-Verlag; 2013. p. 3-12. doi 10.1007/978-1-4471-4288_1.

  4. World Health Organization (WHO). World health statistics 2016: monitoring health for the SDGs, sustainable development goals. Geneva: WHO; 2016. Access: 2017/02/15. Available at: http://www.who.int/about/licensing/copyright_form/en/index.html

  5. Ministerio de Salud Pública. Dirección de Registros Médicos y Estadísticas de Salud. Estadísticas de Salud en Cuba. Anuario Estadístico 2017. La Habana: Minsap; 2018. Acceso: 03/02/2019. Disponible en: http://files.sld.cu/dne/files/2018/04/Anuario-Electronico-Espa%C3%B1ol-2017-ed-2018.pdf

  6. Alegría-Ezquerra E, Alegría-Barrero E, Alegría-Barrero A. La guía europea de dislipemia. Fortalezas y debilidades. Rev Esp Cardiol. 2015;15(Supl A):14-7.

  7. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626-35. doi: 10.1016/S0140-6736(14)61177-6

  8. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, Williams K, Neely B, Sniderman AD, Peterson ED. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370(15):1422-31. doi: 10.1056/NEJMoa1315665.

  9. Bronas UG, Salisbury D. Clinical strategies for managing dyslipidemias. Am J Lifestyle Med. 2013;1-15.

  10. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013:1-84. doi: 10.1161/01.cir.0000437738.63853.7a

  11. Ministerio de Salud Pública. Comité Estatal de Normalización. Buenas Prácticas de Laboratorio. NC-26-212.1992. La Habana: Normas ISO,1992 .

  12. Ministerio de Salud Pública. Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos. Regulación No. 3/95. Buenas Prácticas de Laboratorio Clínico. La Habana: CECMED; 1995.

  13. Pell JP. Heart. Almanac 2012: Cardiovascular risk scores. Clin Cardiol. 2012;98(17):1272-7.

  14. Tunstall-Pedoe H. Cardiovascular risk and risk scores: ASSIGN, Framingham, QRISK and others: how to choose. Heart. 2011;97:442-4.

  15. Morejón Reinoso O, Triana Mantilla ME. Importancia de la interpretación del colesterol total y de los triglicéridos para el diagnóstico de las dislipidemias. Rev Cubana Angiol Cir Vasc. 2015;16(1):54-63. Acceso: 30/01/2019. Disponible en: http://scielo.sld.cu/pdf/ang/v16n1/ang08115.pdf

  16. Bonet Gorbea M, Varona Pérez P, Chang La Rosa M, García Rocha RG, Suárez Medina R, Arcia Montes de Oca N, et al. III Encuesta Nacional de Factores de Riesgo y actividades preventivas de enfermedades no transmisibles. Cuba 2010 – 2011. La Habana: Editorial de Ciencias Médica; 2014.

  17. Khetarpal SA, Rader DJ. Triglyceride-rich lipoproteins and coronary artery disease risk. New insights from human genetics. Arterioscler Thromb Vasc Biol. 2015;35:e3-e9. doi: 10.1161/ATVBAHA.114.305172. Acceso: 30/01/2019. Disponible en: http://atvb.ahajournals.org/content/35/2/e3.full.pdf+html

  18. Pérez de Isla L, Sánchez Fernández PL, Álvarez-Sala Walther L, Barrios Alonso V, Castro Conde A, Galve Basilio E, et al. Comments on the 2016 ESC/ EAS Guidelines for the management of dyslipidemias. Rev Esp Cardiol. 2017;70(2):72-7.

  19. Fanlo Maresma M, Pintó Sala X. Guías de práctica clínica de manejo de la dislipidemia en diabéticos y otros grupos de riesgo. Rev Esp Cardiol. 2015;15(Supl. A):8-13.

  20. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. Guía de práctica clínica de la ESC sobre diabetes, pre-diabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Rev Esp Cardiol. 2014;67(2):136.e1-e56

  21. Sheehan M, Kok HK, Lee M. Principles, signs and symptoms of peripheral vascular disease. In: Kok HK, et al, editors. Interventional Radiology for Medical Students. Alemania: Springer International Publishing AG; 2018. p. 5-14. doi 10.1007/978-3-319-53853-2_2.

  22. Salgado Castillo I, Triana Mantilla ME, Rodríguez Villalonga LE, Arpajón Peña Y. Prevalencia de enfermedades vasculares periféricas en el municipio de Arroyo Naranjo. Rev Cubana Angiol Cir Vasc. 2016;17(2). Acceso: 30/01/2019. Disponible en: http://bvs.sld.cu/revistas/ang/vol17_2_16/ang04216.htm

  23. de la Torre Puente C, Triana Mantilla ME, Rodríguez Villalonga LE, Arpajón Peña Y, Almeida Hernández L, Martínez Góngora I. Enfermedades vasculares periféricas y niveles de calidad de vida en el municipio Diez de Octubre. Rev Cubana Angiol Cir Vasc. 2017;18(1). Acceso: 30/01/2019. Disponible en: http://bvs.sld.cu/revistas/ang/vol18_1_17/ang06117.htm

  24. Terentes-Printzios D, Vlachopoulos Ch, Xaplanteris P, Ioakeimidis N, Aznaouridis K, Baou K, et al. Cardiovascular risk factors accelerate progression of vascular aging in the general population. Results from the CRAVE Study (Cardiovascular Risk Factors Affecting Vascular Age). Hypertension. 2017;70:1057-64. doi: 10.1161/hypertensionaha.117.09633.

  25. Sociedad Argentina de Cardiología (SAC). Consenso de enfermedad vascular periférica. Rev Argent Cardiol. 2015;83(3):1-108.

  26. Chockalingam A, Thakur JS, Varma S. Evolution of non-communicable diseases: Past, present, and future. Intern J Noncomm Dis. 2017;2(1):1-2.




2020     |     www.medigraphic.com